Abstract

Introduction: There is an established role of clinical risk factors such as arterial hypertension and smoking in causing cardiovascular morbidity and diabetic nephropathy (DNP). Genetic factors increase the risk for DNP. To examine the genetic risk, we initiated a case-control study with predefined follow-up examinations. We describe the study design and baseline characteristics under special consideration of comedication, and give preliminary results of the 4-year follow-up. Methods: We enrolled all 477 patients with DNP receiving maintenance hemodialysis in 30 centers in Southern Germany between August 1999 and January 2000. As controls, we enrolled all 482 diabetes mellitus type 2 patients without urinary microalbuminuria in two examinations on consecutive days and without other signs of renal disease in a large diabetes clinic from September 2000 to September 2001. Follow-up examinations are performed 4 and 6 years after inclusion by questionnaire and telephone interview to determine mortality and new morbidity. Controls progressing to novel DNP at follow-up, as defined by semiquantitative dipstick urinary albumin/creatinine ratio > 30 mg/g, are defined as cases in the study’s nested case control component. Results: At study inclusion in cases and controls, respectively, mean age was 67.3 ± 8.2 and 58.1 ± 11.2 years and duration of diabetes mellitus was 15.6 ± 9.6 (at dialysis initiation) and 11.0 ± 8.6 years. 328 controls (of which 25 had died and 14 did not perform urinalysis) were subjected to follow-up at 4 years, at a mean of 3.5 ± 0.8 years after inclusion. 51.2% (n = 148) of living controls remained normalbuminuric, 33.9% (n = 98) had micro- or macroalbuminuria, and in 14.9% (n = 43) the dipstick test was inconclusive. There was no significant difference in progression to micro- or macroalbuminuria between controls treated with ACE or AT-2 inhibitors at baseline or not. Renal function as estimated by the abbreviated MDRD formula declined from 86.8 ± 21.0 to 82.5 ± 22.3 ml/min/1.73 m2 (p < 0.001). The decline was significant in patients on ACE or AT-2 inhibitors at baseline and not in patients without such medication at baseline. Discussion: GENDIAN is a large case-control study designed to evaluate clinical and genetic determinants of DNP and other complications of long-standing diabetes mellitus type 2. We observed an association of ACE or AT-2 inhibitor therapy with cardiovascular comorbidity and a significant decline in renal function after a 4-year follow-up.

*Presented at the 9th NephroPharmacology Meeting in Ulm, Germany 2005

Author Details

Authors

• C.A. Böger¹
• T. Haak²
• A.K. Götz¹
• J. Christ¹
• E. Ruff²
• U. Hoffmann¹
• G.A.J. Riegger¹
• B.K. Krämer¹

Departments

• ¹ Klinik und Poliklinik für Innere Medizin II, University of Regensburg, Regensburg, and
• ² Diabetesklinik Bad Mergentheim, Bad Mergentheim, Germany

Address

Dr. C.A. Böger
Klinik und Poliklinik für Innere Medizin II
Clinic of the University of Regensburg
Franz-Josef-Strauß-Allee 11
93053 Regensburg, Germany
Email: [email protected]

Citation